Last reviewed · How we verify
Ascorbate
Ascorbate, marketed by Dr. Mohammed Milhem, is a drug with a key composition patent expiring in 2028. The drug's market position and primary indication are not specified, but it holds a unique mechanism of action that may provide a competitive edge. The primary risk is the patent expiry in 2028, which could lead to increased competition from generics.
At a glance
| Generic name | Ascorbate |
|---|---|
| Also known as | Ascorbic Acid, Vitamin C, Pharmacological ascorbate, Ascor L 500 |
| Sponsor | Mohammed Milhem, MBBS |
| Drug class | Vitamin D [EPC] |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- The Body's Affect on Vitamin C (PHASE1)
- 177Lu-DOTA-EB-TATE in Adult Patients With Metastatic, Radioactive Iodine Non-Responsive Oncocytic (Hurthle-Cell) Thyroid Cancer (PHASE1, PHASE2)
- A Phase 2 Study Adding Ascorbate to Chemotherapy and Radiation Therapy for NSCLC (PHASE2)
- Investigation of Colgate Dual Zinc Toothpaste as Compared to Colgate Cavity Protection Toothpaste in Controlling Plaque and Gingivitis (PHASE3)
- Ascorbate in Myelodysplastic Syndrome (PHASE2)
- Ascorbate With Durvalumab in Non-Small Cell Lung Cancer (NSCLC) (PHASE1)
- High-dose Ascorbate (HDA) in Combination With Standard of Care Azacitidine and Venetoclax in Acute Myeloid Leukemia (AML) (PHASE1)
- SHARON: A Clinical Trial for Metastatic Cancer Using Chemotherapy and Patients' Own Stem Cells (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Ascorbate CI brief — competitive landscape report
- Ascorbate updates RSS · CI watch RSS
- Mohammed Milhem, MBBS portfolio CI